Notre-Dame Capital

Notre Dame Capital is a private equity and venture capital firm headquartered in Paris, France, specializing in the life sciences, healthcare, and technology sectors. The firm operates as a "company builder," focusing on the creation, financing, and strategic development of innovative biotechnology and medical technology companies. It is most notably recognized for its foundational role in Abivax, a clinical-stage biotech company developing novel therapies for chronic inflammatory diseases. Notre Dame Capital's portfolio also includes significant holdings in companies like Affluent Medical and Pharnext, spanning therapeutic areas such as gastroenterology, neurology, and cardiology. By providing both capital and operational expertise, the firm aims to accelerate the transition of high-impact scientific research into commercial medical solutions. The firm typically maintains a long-term investment horizon, supporting its portfolio companies through various stages of clinical development and market entry.